The company also intends to eventually offer the two additions, which expand the granularity of its live-cell analysis platform, for clinical use.
In a recent study, a pair of proteins identified women who went on to deliver preterm with specificity and sensitivity of 78 and 80 percent, respectively.
While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
Researchers believe the expression of Gabra3 promotes breast cancer metastasis, but that an RNA-edited form of Gabra3 suppresses it.
Jeff Huber, former Google X senior vice president, joins Grail as its CEO.
In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.
Japan needs to catch up on its gene-editing research efforts, the Japan News writes.
Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.